drugset
drugset / Trial / NCT03866798

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

NCT03866798 ↗

Phase 4 Terminated 6 enrolled Octapharma
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, open-label, single-arm, multicenter, Phase 4 study evaluating the efficacy and safety of PANZYGA in pediatric patients with chronic ITP.

Timeline

Start
2020-01-21
Primary completion
2023-09-19
Completion
2024-05-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic — Intravenous

Indications

autoimmune thrombocytopenia